Avatan0.004%

Avatan 0.004% Eye Drops is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension who are intolerant of or insufficiently responsive to another intraocular pressure lowering medication, as monotherapy or as adjunctive therapy.

Drugs for miotics and glaucoma

Avatan 0.004%, an isopropyl ester prodrug, is a synthetic prostaglandin F2 alpha analogue that is rapidly hydrolyzed by esterases in the cornea to its biologically active free acid. The travoporst free acid is potent and highly selective for the FP prostanoid receptor.Avatan 0.004% free acid is a selective FP prostanoid receptor agonist and is believed to reduce intraocular pressure by increasing the drainage of aqueous humor, which is done primarily through increased uveoscleral outflow and to a lesser extent, trabecular outflow facility.

Use in adults: The recommended dose is one drops of Avatan 0.004% in the conjunctival sac of the affected eye (s) once daily in the evening, If more than one topical ophthalmic product is being used, the medicines must be administered at least 5 minutes apart. When substituting another ophthalmic antiglaucoma agent with Avatan 0.004%, discontinue the other agent and start the following day with Avatan 0.004%.Pediatric patients: The efficacy and safety of Avatan 0.004% eye drops in patients below the age of 18 years have not been established.

Use in adults: The recommended dose is one drops of Avatan 0.004% in the conjunctival sac of the affected eye (s) once daily in the evening, If more than one topical ophthalmic product is being used, the medicines must be administered at least 5 minutes apart. When substituting another ophthalmic antiglaucoma agent with Avatan 0.004%, discontinue the other agent and start the following day with Avatan 0.004%.Pediatric patients: The efficacy and safety of Avatan 0.004% eye drops in patients below the age of 18 years have not been established.

Reduced therapeutic effect with NSAIDs.

Avatan 0.004% eye drops is contraindicated in patients with hypersensitive to Avatan 0.004% or any excipients of this preparation.

The most frequently reported treatment-related side-effect is ocular hyperaemia.

There are no adequate and well-controlled clinical study En pregnant women. Avatan 0.004% should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.It is not known whether the drug or its metabolites are excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Avatan 0.004% is administered to a lactating woman.

Avatan 0.004% should be used with caution in patients with active intraocular inflammation (iritis/uveitis). Avatan 0.004% should not be administered while wearing contact lenses. Contact lenses should be removed prior to the administration of the solution. Lenses may be reinserted 15 minutes following administration of Avatan 0.004%.

Store in a cool, dry place and protected from light. Keep out of reach of children. Discard the container 4 weeks after opening.

Drugs for miotics and glaucoma

Avatan 0.004%, an isopropyl ester prodrug, is a synthetic prostaglandin F2 alpha analogue that is rapidly hydrolyzed by esterases in the cornea to its biologically active free acid. The travoporst free acid is potent and highly selective for the FP prostanoid receptor.Avatan 0.004% free acid is a selective FP prostanoid receptor agonist and is believed to reduce intraocular pressure by increasing the drainage of aqueous humor, which is done primarily through increased uveoscleral outflow and to a lesser extent, trabecular outflow facility.

There are no adequate and well-controlled clinical study En pregnant women. Avatan 0.004% should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.It is not known whether the drug or its metabolites are excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Avatan 0.004% is administered to a lactating woman.